Ultragenyx Faces Class Action, Operational Cuts After Setrusumab Phase 3 Failures

Ultragenyx Faces Class Action and Operational Review After Setrusumab Trial Failures

Ultragenyx Pharmaceutical is confronting a class action securities lawsuit and an internal operational reassessment after late‑stage failures of its lead bone disease candidate, setrusumab (UX143). Law firm Kahn Swick & Foti (KSF), together with partner Charles C. Foti Jr., notifies investors of a suit filed on behalf of purchasers of Ultragenyx securities, alleging securities fraud tied to disclosures made on Dec. 26, 2025. The legal notice is published via PR Newswire on Feb. 13, 2026 and the complaint is captioned Steven Bailey v. Ultragenyx Pharmaceutical Inc., No. 26‑cv‑01097.

The litigation stems from Ultragenyx’s announcement that two Phase 3 trials, Orbit and Cosmic, in patients with osteogenesis imperfecta fail to show a statistically significant reduction in annualised fracture rates. In response to those results, the company says it is evaluating planned operations and will “promptly define and implement significant expense reductions.” Plaintiffs allege losses arising from the company’s statements during a class period they define from Aug. 3, 2023 through Dec. 26, 2025, and seek recovery for affected investors.

The dispute raises immediate strategic questions for Ultragenyx, a specialist in rare disease therapeutics, about how it reallocates resources across its pipeline and clinical programmes. Management’s commitment to substantial expense reductions signals potential program slowdowns, workforce adjustments or reprioritisation of development candidates. For a company focused on low‑prevalence conditions where development costs are high and clinical readouts are binary, a failed Phase 3 can force rapid operational changes to preserve cash and sustain other late‑stage efforts.

Legal Process and Investor Options

KSF invites potentially eligible investors to seek lead‑plaintiff status and to preserve their rights; investors who bought Ultragenyx securities during the defined class period have until April 6, 2026 to move the court for appointment as lead plaintiff. The firm provides a case webpage and a toll‑free contact for questions and claim submissions to determine eligibility for any potential recovery.

Background on Setrusumab and Industry Context

Setrusumab, an antibody therapy aimed at reducing fractures in osteogenesis imperfecta, represents a high‑risk, high‑reward strategy common in rare‑disease biotech. The Phase 3 Orbit and Cosmic readouts failing to meet their primary endpoint underline the technical and regulatory challenges facing companies developing treatments for genetically driven bone disorders, and increase pressure on sponsors to demonstrate robust, clinically meaningful benefits to justify continued investment.